Oxidation of Drugs during Drug Product Development: Problems and Solutions

Area of Science:

• Pharmaceutical Science
• Drug Degradation Studies
• Solid-State Chemistry

Background:

• Oxidation is a major pharmaceutical degradation pathway, second only to hydrolysis.
• Unlike hydrolysis, oxidation is mechanistically complex, yielding diverse degradation products and posing control challenges.
• Excipients in drug formulations are common sources of impurities that can initiate solid-state drug oxidation.

Purpose of the Study:

• To review common oxidation mechanisms in pharmaceuticals.
• To identify sources of reactive oxygen species in drug products.
• To outline strategies for minimizing drug oxidation in the solid state.

Main Methods:

• Forced degradation studies establish a drug's susceptibility to oxidation.
• Accelerated stability studies of drug-excipient mixtures provide realistic solid-state degradation insights.
• Analysis of degradation products and identification of critical parameters.

Main Results:

• Excipient-derived impurities are key initiators of solid-state drug oxidation.
• Understanding oxidation mechanisms and reactive oxygen species sources is crucial.
• Well-planned accelerated studies enable the identification of critical control parameters.

Conclusions:

• Accelerated studies of drug-excipient mixtures are vital for predicting and controlling pharmaceutical oxidation.
• Proactive identification of critical parameters minimizes oxidation-related quality issues.
• Minimizing oxidation ensures the long-term stability and efficacy of solid drug products.